Micotar (Miconazole)

Miconazole inhibits the fungal enzyme lanosterol 14α‑demethylase, blocking ergosterol synthesis essential for fungal cell membranes. This disruption leads to increased membrane permeability and fungal cell death, providing targeted antifungal activity at the site of application.

The dosage and duration of Micotar are determined by the prescribing healthcare professional based on the severity of the infection and patient-specific factors. Patients should follow the prescriber’s instructions and the product label.

Safety of miconazole buccal products in pregnancy or lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Micotar.

To request Micotar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Micotar delivers miconazole directly to the oral cavity, offering rapid local action with minimal systemic exposure. Compared with systemic azoles, it reduces the risk of systemic side effects, while providing efficacy comparable to other topical agents such as clotrimazole lozenges for oral candidiasis.

Micotar should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Micotar is applied buccally, meaning the tablet or lozenge is placed in the mouth and allowed to dissolve slowly, ensuring contact with the oral mucosa. Patients should follow the prescribed frequency and avoid swallowing the product whole before it dissolves.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and hepatic dysfunction. Any signs of rash, fever, jaundice, or difficulty breathing should prompt immediate medical attention.

Micotar should not be used by individuals with a known hypersensitivity to miconazole or other imidazole antifungals. Patients with severe liver disease or those taking contraindicated medications that strongly interact with miconazole should also avoid its use unless directed by a clinician.